FMP

FMP

Enter

SUPN - Supernus Pharmaceuti...

Financial Summary of Supernus Pharmaceuticals, Inc.(SUPN), Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commerci

photo-url-https://financialmodelingprep.com/image-stock/SUPN.png

Supernus Pharmaceuticals, Inc.

SUPN

NASDAQ

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

29.31 USD

-0.95 (-3.24%)

About

ceo

Mr. Jack A. Khattar

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

website

https://www.supernus.com

exchange

NASDAQ

Description

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hy...

CIK

0001356576

ISIN

US8684591089

CUSIP

868459108

Address

9715 Key West Avenue

Phone

301 838 2500

Country

US

Employee

652

IPO Date

May 1, 2012

Summary

CIK

0001356576

Exchange

NASDAQ

Industry

Drug Manufacturers -...

Sector

Healthcare

CUSIP

868459108

ISIN

US8684591089

Country

US

Price

29.31

Beta

0.99

Volume Avg.

389.27k

Market Cap

1.6B

Shares

-

52-Week

21.99-38.09

DCF

74.59

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

1.47k

P/B

-

Website

https://www.supernus.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest SUPN News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep